Science

Our Data

We pride ourselves on the innovative science behind our therapies that bring real results to real people. See firsthand the impact our data are making.

Rilonacept

November 17, 2019

Presentation: Real-World Clinical Characteristics and Recurrence Burden of Patients Diagnosed with Recurrent Pericarditis in the United States

David Lin, Christine Majeski, Maral DerSarkissian, et al.

Presented at American Heart Association (AHA) Scientific Sessions 2019

November 17, 2019

Presentation: Intensification of the Inflammasome Formation in the Pericardium of Patients with Chronic Severe Pericarditis

Aldo Bonaventura, Antonio Cannatà, Eleonora Mezzaroma, et al.

Presented at American Heart Association (AHA) Scientific Sessions 2019

November 16, 2019

Presentation: Predictors of Adverse Outcomes in Patients with Acute Pericarditis

Alessandra Vecchié, Juan Guido Chiabrando, Megan Dell, et al.

Presented at American Heart Association (AHA) Scientific Sessions 2019

November 16, 2019

Presentation: Efficacy and Safety of Rilonacept in Recurrent Pericarditis: A Multicenter Phase 2 Clinical Trial

Allan Klein, David Lin, Paul Cremer, et al.

Presented at American Heart Association (AHA) Scientific Sessions 2019

September 9, 2019

Presentation: Recurrent Pericarditis Epidemiology in the United States (2013-2018)

Allan Klein, Paul Cremer, Apostolos Kontzias, et al.

Presented at the American College of Epidemiology (ACE) 2019 Annual Meeting

September 2, 2019

Presentation: RHAPSODY: A Pivotal Phase 3 Trial to Assess Efficacy and Safety of Rilonacept, an Interleukin 1 Alpha and Interleukin 1 Beta Blocker, in Patients With Recurrent Pericarditis

Massimo Imazio, Allan Klein, Antonio Brucato, et al.

Presented at the European Society of Cardiology (ESC) Congress 2019

May 18-22, 2019

Unmet needs and burden of recurrent pericarditis (RP): results of a systematic literature review (SLR)

Crotty C, Forsythe A, Magestro M.

Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), New Orleans, LA

March 16-18, 2019

Rilonacept in recurrent pericarditis: first efficacy and safety data from an ongoing phase 2 pilot clinical trial

Klein A, Lin D, Cremer P, et al.

Presented at the 68th Annual Scientific Session of the American College of Cardiology (ACC), New Orleans, LA

Top

Mavrilimumab

November 12, 2019

Presentation: GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis

Maria C. Cid, Rohan Gandhi, Marc Corbera-Bellalta, et al.

Presented at 2019 American College of Rheumatology (ACR) Annual Meeting

November 11, 2019

Presentation: GM-CSF is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries

Ryu Watanabe, Hui Zhang, Toshihisa Maeda, et al.

Presented at 2019 American College of Rheumatology (ACR) Annual Meeting

June 13, 2019

Presentation: GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients With Giant Cell Arteritis

Maria C. Cid, Rohan Gandhi, Marc Corbera-Bellalta, et al.

Presented at the European Congress of Rheumatology (EULAR) 2019

April 7-10, 2019

A phase 2, randomized, double-blind, placebo-controlled study to test the efficacy and safety of mavrilimumab in giant cell arteritis: study design and methodology

Pupim L, Unizony SH, Cid MC, et al.

Presented at Vasculitis 2019: the 19th International Vasculitis and ANCA Workshop, Philadelphia, PA

Top

KPL-716

October 22, 2019

Presentation: A Population Pharmacokinetic Model of KPL-716 In Healthy Volunteers and Patients with Atopic Dermatitis

Steve Choy, Wanchana Ungphakorn Fran Stringer, et al.

Presented at the Tenth American Conference on Pharmacometrics (ACoP10)

October 9, 2019

Presentation: IL-31 is Implicated in the Pathogenesis of Prurigo Nodularis, a Chronic Pruritic Skin Disease that can Exist Irrespective of Co-morbid Conditions (LOTUS-PN Study)

Sonja Ständer , Zamaneh Mikhak , Tim Berger, et al.

Presented at the 28th European Academy of Dermatology and Venereology (EADV), Madrid, Spain

September 19, 2019

Presentation: Increased Expression of Oncostatin M Receptor β in Chronic Pruritic Diseases

Rohan Gandhi, Anna De Benedetto, Sujatha Muralidharan, et al.

Presented at the 49th Annual Meeting of the European Society of Dermatological Research (ESDR)

May 8-11, 2019

KPL-716, an anti-oncostatin M receptor beta (OSMRβ) monoclonal antibody, reduces IL-31–induced scratching behavior in cynomolgus monkeys: establishment and optimization of a pharmacokinetic/pharmacodynamic model

Gandhi R, Crowder K, Barrow K, et al.

Presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID), Chicago, IL

May 8-11, 2019

KPL-716, anti-oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis

Mikhak Z, Bissonette R, Siri D, et al.

Presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID), Chicago, IL

May 8-11, 2019

The oncostatin M receptor beta axis identified in prurigo nodularis

Mikhak Z, Ständer S, Guttman E, et al.

Presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID), Chicago, IL

May 8-11, 2019

Oncostatin M induction of monocyte chemoattractant protein 1 (MCP-1) in human epidermal keratinocytes is inhibited by anti-oncostatin M receptor β monoclonal antibody KPL-716

Richards CD, Gandhi R, Botelho F, et al.

Presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID), Chicago, IL

April 6-7, 2019

Safety, tolerability and anti-pruritic effect of KPL-716, anti-oncostatin M receptor beta monoclonal antibody, from a phase 1a/1b clinical trial in healthy volunteers and participants with atopic dermatitis

Mikhak Z, Neutel JM, Bissonnette R, et al.

Presented at the Revolutionizing Atopic Dermatitis (RAD) Conference, Chicago, IL

Top

KPL-404

April 7-11, 2019

KPL-404, a CD40 antagonist, blocked antigen-specific antibody responses in an in vivo NHP model and demonstrated strong PK/PD correlation

Muralidharan S, Classon BJ, Crowder K, et al.

Presented at the Keystone Symposia: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies, Breckenridge, CO

Top